This company has been marked as potentially delisted and may not be actively trading. TradeUP Acquisition (UPTD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock UPTD vs. NKGN, AIM, SRNE, SQZ, GNCAQ, GNCA, ELOX, PRME, PLX, and IKTShould you be buying TradeUP Acquisition stock or one of its competitors? The main competitors of TradeUP Acquisition include NKGen Biotech (NKGN), AIM ImmunoTech (AIM), Sorrento Therapeutics (SRNE), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Protalix BioTherapeutics (PLX), and Inhibikase Therapeutics (IKT). These companies are all part of the "biological products, except diagnostic" industry. TradeUP Acquisition vs. Its Competitors NKGen Biotech AIM ImmunoTech Sorrento Therapeutics SQZ Biotechnologies Genocea Biosciences Genocea Biosciences Eloxx Pharmaceuticals Prime Medicine Protalix BioTherapeutics Inhibikase Therapeutics TradeUP Acquisition (NASDAQ:UPTD) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Is UPTD or NKGN more profitable? Company Net Margins Return on Equity Return on Assets TradeUP AcquisitionN/A N/A -3.38% NKGen Biotech N/A N/A -479.36% Which has more risk & volatility, UPTD or NKGN? TradeUP Acquisition has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Does the media favor UPTD or NKGN? In the previous week, NKGen Biotech had 2 more articles in the media than TradeUP Acquisition. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for TradeUP Acquisition. TradeUP Acquisition's average media sentiment score of 0.67 beat NKGen Biotech's score of -0.50 indicating that TradeUP Acquisition is being referred to more favorably in the media. Company Overall Sentiment TradeUP Acquisition Positive NKGen Biotech Negative Do institutionals and insiders hold more shares of UPTD or NKGN? 35.0% of TradeUP Acquisition shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 55.1% of TradeUP Acquisition shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, UPTD or NKGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTradeUP AcquisitionN/AN/A-$1MN/AN/ANKGen BiotechN/AN/A-$82.94M-$2.45-0.06 SummaryTradeUP Acquisition beats NKGen Biotech on 4 of the 7 factors compared between the two stocks. Get TradeUP Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for UPTD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPTD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPTD vs. The Competition Export to ExcelMetricTradeUP AcquisitionBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78M$281.95M$5.44B$9.61BDividend YieldN/AN/A4.61%4.14%P/E RatioN/AN/A29.7624.84Price / SalesN/A462.25449.1298.65Price / CashN/A22.4436.4258.36Price / Book-0.528.908.185.64Net Income-$1M-$115.81M$3.26B$265.68M TradeUP Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPTDTradeUP AcquisitionN/A$0.82-2.3%N/A-39.2%$1.78MN/A0.002,021NKGNNKGen Biotech0.4858 of 5 stars$0.14flatN/A-86.3%$6.29MN/A-0.03N/AShort Interest ↑Gap UpAIMAIM ImmunoTech1.1346 of 5 stars$2.83-3.1%$275.00+9,617.3%-91.1%$2.16M$146K-6.0220Gap DownHigh Trading VolumeSRNESorrento Therapeutics0.8727 of 5 stars$0.00flatN/A-81.3%$827K$60.32M0.00800High Trading VolumeSQZSQZ BiotechnologiesN/A$0.03flatN/AN/A$826K$18.16M-0.011,620Positive NewsGNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ELOXEloxx PharmaceuticalsN/A$0.00flatN/AN/A$0.00N/A0.0030Gap DownPRMEPrime Medicine3.7765 of 5 stars$4.04+8.0%$9.25+129.0%-13.7%$503.02M$3.85M-1.97234Analyst ForecastPLXProtalix BioTherapeutics2.6448 of 5 stars$1.45-0.7%$15.00+934.5%+46.7%$115.43M$59.76M-11.15200IKTInhibikase Therapeutics1.6425 of 5 stars$1.52-3.8%$6.50+327.6%+11.7%$113MN/A-0.576 Related Companies and Tools Related Companies NKGen Biotech Alternatives AIM ImmunoTech Alternatives Sorrento Therapeutics Alternatives SQZ Biotechnologies Alternatives Genocea Biosciences Alternatives Genocea Biosciences Alternatives Eloxx Pharmaceuticals Alternatives Prime Medicine Alternatives Protalix BioTherapeutics Alternatives Inhibikase Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPTD) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TradeUP Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share TradeUP Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
